CD276 and cancer: In conclusion, the present study has shown that CD276 is expressed differently in different cancers and at different stages of cancer development, suggesting that CD276 may exert different roles in different cancers, although, overall, high expression of CD276 in the majority of different types of cancer is associated with poor patient prognosis, poor survival and poor clinical outcomes.